Delirium Tremens (DTs): Emergency Management

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
  VerticalAlign, PageNumber, Header, Footer, TableOfContents,
  UnderlineType
} = require('docx');
const fs = require('fs');

// ── Color palette ──────────────────────────────────────────────────────────
const DARK_BLUE   = "1B3A6B";
const MED_BLUE    = "2E6DAD";
const LIGHT_BLUE  = "D6E4F0";
const ACCENT      = "C0392B";   // red for warnings
const LIGHT_GREY  = "F2F4F6";
const WHITE       = "FFFFFF";
const DARK_TEXT   = "1A1A2E";

// ── Helpers ─────────────────────────────────────────────────────────────────
const noBorder = { style: BorderStyle.NONE, size: 0, color: "FFFFFF" };
const thinBorder = { style: BorderStyle.SINGLE, size: 4, color: "CCCCCC" };
const thickBlueBorder = { style: BorderStyle.SINGLE, size: 12, color: MED_BLUE };

function h1(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_1,
    spacing: { before: 360, after: 120 },
    border: { bottom: { style: BorderStyle.SINGLE, size: 8, color: MED_BLUE } },
    children: [new TextRun({ text, bold: true, color: DARK_BLUE, size: 28, font: "Calibri" })],
  });
}

function h2(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_2,
    spacing: { before: 280, after: 80 },
    children: [new TextRun({ text, bold: true, color: MED_BLUE, size: 24, font: "Calibri" })],
  });
}

function h3(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_3,
    spacing: { before: 200, after: 60 },
    children: [new TextRun({ text, bold: true, color: DARK_BLUE, size: 22, font: "Calibri" })],
  });
}

function para(text, opts = {}) {
  return new Paragraph({
    spacing: { after: 120, line: 276 },
    children: [new TextRun({
      text,
      size: 20,
      font: "Calibri",
      color: DARK_TEXT,
      ...opts
    })],
  });
}

function bullet(text, level = 0) {
  return new Paragraph({
    bullet: { level },
    spacing: { after: 80 },
    children: [new TextRun({ text, size: 20, font: "Calibri", color: DARK_TEXT })],
  });
}

function keyValue(key, value) {
  return new Paragraph({
    spacing: { after: 80 },
    children: [
      new TextRun({ text: key + ": ", bold: true, size: 20, font: "Calibri", color: DARK_BLUE }),
      new TextRun({ text: value, size: 20, font: "Calibri", color: DARK_TEXT }),
    ],
  });
}

function warningBox(text) {
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [
      new TableRow({
        children: [
          new TableCell({
            shading: { type: ShadingType.SOLID, color: "FDECEA" },
            borders: {
              top: { style: BorderStyle.SINGLE, size: 8, color: ACCENT },
              bottom: { style: BorderStyle.SINGLE, size: 8, color: ACCENT },
              left: { style: BorderStyle.THICK, size: 16, color: ACCENT },
              right: noBorder,
            },
            margins: { top: 80, bottom: 80, left: 120, right: 120 },
            children: [
              new Paragraph({
                children: [
                  new TextRun({ text: "⚠  ", bold: true, color: ACCENT, size: 20, font: "Calibri" }),
                  new TextRun({ text, bold: true, color: ACCENT, size: 20, font: "Calibri" }),
                ],
              }),
            ],
          }),
        ],
      }),
    ],
  });
}

function infoBox(title, lines) {
  const children = [
    new Paragraph({
      spacing: { after: 60 },
      children: [new TextRun({ text: title, bold: true, size: 22, color: WHITE, font: "Calibri" })],
    }),
    ...lines.map(l => new Paragraph({
      spacing: { after: 60 },
      children: [new TextRun({ text: l, size: 20, color: WHITE, font: "Calibri" })],
    })),
  ];
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [
      new TableRow({
        children: [
          new TableCell({
            shading: { type: ShadingType.SOLID, color: DARK_BLUE },
            borders: { top: noBorder, bottom: noBorder, left: noBorder, right: noBorder },
            margins: { top: 120, bottom: 120, left: 160, right: 160 },
            children,
          }),
        ],
      }),
    ],
  });
}

function spacer(size = 120) {
  return new Paragraph({ spacing: { after: size }, children: [new TextRun("")] });
}

function makeTable(headers, rows, colWidths) {
  const headerRow = new TableRow({
    tableHeader: true,
    children: headers.map((h, i) => new TableCell({
      width: colWidths ? { size: colWidths[i], type: WidthType.PERCENTAGE } : undefined,
      shading: { type: ShadingType.SOLID, color: DARK_BLUE },
      borders: { top: noBorder, bottom: noBorder, left: noBorder, right: noBorder },
      margins: { top: 80, bottom: 80, left: 100, right: 100 },
      children: [new Paragraph({
        children: [new TextRun({ text: h, bold: true, color: WHITE, size: 18, font: "Calibri" })],
      })],
    })),
  });

  const dataRows = rows.map((row, ri) => new TableRow({
    children: row.map((cell, ci) => new TableCell({
      width: colWidths ? { size: colWidths[ci], type: WidthType.PERCENTAGE } : undefined,
      shading: { type: ShadingType.SOLID, color: ri % 2 === 0 ? WHITE : LIGHT_GREY },
      borders: {
        top: thinBorder, bottom: thinBorder,
        left: noBorder, right: noBorder,
      },
      margins: { top: 60, bottom: 60, left: 100, right: 100 },
      children: [new Paragraph({
        children: [new TextRun({ text: cell, size: 18, font: "Calibri", color: DARK_TEXT })],
      })],
    })),
  }));

  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [headerRow, ...dataRows],
  });
}

// ── Title Page ───────────────────────────────────────────────────────────────
function titlePage() {
  return [
    spacer(600),
    new Table({
      width: { size: 100, type: WidthType.PERCENTAGE },
      rows: [new TableRow({
        children: [new TableCell({
          shading: { type: ShadingType.SOLID, color: DARK_BLUE },
          borders: { top: noBorder, bottom: noBorder, left: noBorder, right: noBorder },
          margins: { top: 400, bottom: 400, left: 400, right: 400 },
          children: [
            new Paragraph({
              alignment: AlignmentType.CENTER,
              spacing: { after: 120 },
              children: [new TextRun({
                text: "ALCOHOL WITHDRAWAL SEIZURES",
                bold: true, color: WHITE, size: 44, font: "Calibri",
              })],
            }),
            new Paragraph({
              alignment: AlignmentType.CENTER,
              spacing: { after: 80 },
              children: [new TextRun({
                text: "Clinical Reference Document",
                color: LIGHT_BLUE, size: 28, font: "Calibri",
              })],
            }),
            new Paragraph({
              alignment: AlignmentType.CENTER,
              children: [new TextRun({
                text: "Pathophysiology · Diagnosis · Emergency Management · Evidence-Based Treatment",
                color: LIGHT_BLUE, size: 20, font: "Calibri", italics: true,
              })],
            }),
          ],
        })],
      })],
    }),
    spacer(400),
    new Paragraph({
      alignment: AlignmentType.CENTER,
      children: [new TextRun({ text: "Prepared: June 2026", size: 18, color: "888888", font: "Calibri", italics: true })],
    }),
    new Paragraph({
      alignment: AlignmentType.CENTER,
      children: [new TextRun({
        text: "Sources: Tintinalli's Emergency Medicine · Rosen's Emergency Medicine · Bradley & Daroff's Neurology · Textbook of Family Medicine · Kaplan & Sadock's Psychiatry · Harrison's Principles of Internal Medicine · PubMed 2026",
        size: 16, color: "888888", font: "Calibri", italics: true,
      })],
    }),
    new Paragraph({ pageBreakBefore: true, children: [new TextRun("")] }),
  ];
}

// ── Document Sections ────────────────────────────────────────────────────────
const sections = [
  // ── SECTION 1: Overview ────────────────────────────────────────────────
  h1("1. Overview"),
  para(
    "Alcohol withdrawal seizures (AWS) are acute symptomatic seizures occurring in the context of alcohol cessation or significant reduction in intake in alcohol-dependent individuals. Although often self-limited, they carry meaningful risk of progression to status epilepticus (~3%) and signal a higher risk of developing delirium tremens (approximately one third of patients who seize will progress to DTs). Prompt recognition and treatment are essential."
  ),
  spacer(80),
  infoBox("Key Facts at a Glance", [
    "• Onset: typically 6-48 hours after last drink (peak risk 24-48 hours)",
    "• Seizure type: generalized tonic-clonic in >90% of cases",
    "• Multiple seizures in 60% of cases — usually within a 6-hour flurry",
    "• Status epilepticus: rare but possible (<3% of withdrawal seizures)",
    "• ~1/3 of patients with withdrawal seizures progress to delirium tremens",
    "• Mortality (untreated DTs): up to 15%; with early treatment: <5%",
    "• First-line treatment: benzodiazepines (GABA-A potentiation)",
    "• Phenytoin is INEFFECTIVE for alcohol withdrawal seizures",
  ]),
  spacer(),

  // ── SECTION 2: Pathophysiology ─────────────────────────────────────────
  h1("2. Pathophysiology"),
  para("Chronic alcohol consumption produces neuroadaptive changes in two major neurotransmitter systems:"),
  spacer(60),

  h2("2.1 GABAergic System"),
  para("Alcohol is a positive allosteric modulator of GABA-A receptors, producing inhibitory CNS effects. With chronic exposure, the brain compensates by:"),
  bullet("Downregulating and desensitizing GABA-A receptors"),
  bullet("Reducing GABA synthesis and release"),
  bullet("Increasing GABA-A receptor density (chronic upregulation)"),
  para("Abrupt cessation removes alcohol's GABAergic support, leaving the brain in a state of GABA deficiency and unopposed excitatory drive."),
  spacer(60),

  h2("2.2 Glutamatergic System (NMDA Receptors)"),
  para("Alcohol chronically inhibits NMDA glutamate receptors. In adaptation, the brain upregulates NMDA receptor density and sensitivity. On cessation:"),
  bullet("Upregulated NMDA receptors become overactive"),
  bullet("Glutamate excess drives neuronal hyperexcitability"),
  bullet("Combined GABA deficiency + glutamate excess = seizure threshold reduction"),
  para("This neuroadaptive imbalance between inhibitory GABAergic and excitatory glutamatergic systems is the central mechanism underlying AWS. (Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Harrison's Principles of Internal Medicine, 22nd ed.)"),
  spacer(60),

  h2("2.3 Kindling Effect"),
  para("Repeated episodes of alcohol withdrawal lower the seizure threshold with each successive withdrawal episode — a process termed 'kindling.' Patients with a history of prior withdrawal seizures or DTs are at significantly higher risk with each subsequent withdrawal episode. This progressive neurological sensitization has important implications for early intervention and long-term management."),
  spacer(60),

  h2("2.4 Dopamine and Noradrenergic Contributions"),
  para("Autonomic hyperactivity (tachycardia, hypertension, diaphoresis, hyperthermia) reflects increased noradrenergic and dopaminergic tone in the setting of reduced GABA inhibition. These features characterize the broader alcohol withdrawal syndrome that accompanies seizures."),
  spacer(),

  // ── SECTION 3: Clinical Presentation ──────────────────────────────────
  h1("3. Clinical Presentation & Timeline"),
  para("Alcohol withdrawal exists on a continuum. The table below summarizes the typical temporal evolution:"),
  spacer(80),
  makeTable(
    ["Timeframe", "Manifestations", "Clinical Notes"],
    [
      ["6 - 24 hours", "Minor symptoms: anxiety, insomnia, anorexia, nausea/vomiting, headache, palpitations, tremor", "Can be mild; many patients do not require medical care"],
      ["12 - 48 hours", "Alcohol withdrawal seizures (peak risk 24-48 h)", "Generalized tonic-clonic; may occur in a flurry; ~1/3 progress to DTs"],
      ["12 - 24 hours", "Alcoholic hallucinosis: visual > tactile > auditory hallucinations", "NO autonomic instability; distinct from DTs; resolves within 24-48 h"],
      ["48 - 96 hours", "Delirium tremens: delirium + autonomic hyperactivity + hallucinations", "Life-threatening; mortality up to 5% with treatment; requires ICU"],
    ],
    [20, 50, 30]
  ),
  spacer(),

  h2("3.1 Characteristics of Alcohol Withdrawal Seizures"),
  bullet("Type: generalized tonic-clonic (grand mal) in >90% of cases"),
  bullet("90% of patients have 1-6 seizures; 60% occur in a 6-hour flurry"),
  bullet("Usually brief with a short or absent postictal period"),
  bullet("Partial/focal seizures are uncommon — if present, investigate for structural cause"),
  bullet("Status epilepticus is rare (<3%) in isolated alcohol withdrawal"),
  bullet("Seizures may be the first manifestation of withdrawal (can precede other symptoms)"),
  bullet("Pattern tends to recur similarly in the same patient across episodes"),
  spacer(60),

  warningBox("RED FLAGS requiring urgent investigation: Focal seizures, focal postictal deficit, fever with altered mental status, first-ever seizure without prior alcohol history, failure to return to baseline — consider CNS infection, intracranial hemorrhage, or metabolic emergency."),
  spacer(),

  // ── SECTION 4: Risk Factors ───────────────────────────────────────────
  h1("4. Risk Factors"),
  h2("4.1 Risk Factors for Developing Withdrawal Seizures"),
  makeTable(
    ["Risk Factor", "Clinical Significance"],
    [
      ["Prior alcohol withdrawal seizures", "Most powerful predictor — kindling effect; each episode lowers threshold"],
      ["Prior delirium tremens", "High risk of recurrence with subsequent withdrawal"],
      ["Heavy, prolonged alcohol intake (>15 units/day)", "Severity correlates with duration and quantity of dependence"],
      ["Abrupt rather than gradual cessation", "Faster drop in blood alcohol = more severe withdrawal"],
      ["Concurrent medical illness", "Hepatitis, pancreatitis, infection precipitate more severe withdrawal"],
      ["Older age", "Reduced CNS reserve; more severe manifestations"],
      ["Benzodiazepine or other sedative co-use", "Additive withdrawal; may delay or worsen seizures"],
      ["Polydrug use", "Combined withdrawal syndromes"],
      ["Genetic polymorphisms (SLC6A3, APOE)", "Modulate individual vulnerability (2026 evidence — PMID 42095715)"],
      ["History of multiple prior detoxifications", "Kindling effect cumulative over time"],
    ],
    [45, 55]
  ),
  spacer(),

  // ── SECTION 5: Diagnosis ─────────────────────────────────────────────
  h1("5. Diagnosis & Assessment"),

  h2("5.1 Diagnosis of Alcohol Withdrawal Seizure"),
  para("The diagnosis is clinical and is based on:"),
  bullet("History of recurrent events temporally related to ceasing or decreasing alcohol intake"),
  bullet("Generalized tonic-clonic seizure onset 6-48 hours after last drink"),
  bullet("Exclusion of other causes (see differential below)"),
  para("Important: Withdrawal is frequently preceded by an illness or injury that leads to decreased alcohol consumption. Always ask about the precipitating reason for abstinence and assess for concomitant illness. (Rosen's Emergency Medicine)"),
  spacer(60),

  h2("5.2 CIWA-Ar Severity Assessment"),
  para("The Clinical Institute Withdrawal Assessment for Alcohol - Revised (CIWA-Ar) is the validated 10-item tool to quantify withdrawal severity and guide medication dosing:"),
  spacer(60),
  makeTable(
    ["CIWA-Ar Domain", "Scoring Range", "Severe Manifestation"],
    [
      ["Nausea / vomiting", "0-7", "Constant nausea with vomiting"],
      ["Tremor", "0-7", "Severe tremor even with arms extended"],
      ["Paroxysmal sweats", "0-7", "Drenching sweats"],
      ["Anxiety", "0-7", "Acute panic state"],
      ["Tactile disturbances", "0-7", "Continuous hallucinations (bugs crawling on/under skin)"],
      ["Auditory disturbances", "0-7", "Continuous auditory hallucinations"],
      ["Visual disturbances", "0-7", "Continuous visual hallucinations"],
      ["Headache / band sensation", "0-7", "Extremely severe headache"],
      ["Agitation", "0-7", "Pacing or thrashing throughout interview"],
      ["Orientation / clouding", "0-4", "Disoriented to place or person"],
    ],
    [40, 20, 40]
  ),
  spacer(80),
  makeTable(
    ["Total CIWA-Ar Score", "Severity", "Action"],
    [
      ["< 8", "Mild withdrawal", "Monitor; pharmacotherapy may not be required"],
      ["8 - 14", "Moderate withdrawal", "Benzodiazepine; repeat every 2 hours until score <8"],
      ["> 15", "Severe withdrawal", "Benzodiazepine; repeat every 1 hour until score <15"],
    ],
    [25, 25, 50]
  ),
  spacer(60),
  para("Limitation: 7 of 10 CIWA-Ar components require patient communication. Language barriers, sedation, intubation, or co-morbidity may impair accurate scoring. (Tintinalli's Emergency Medicine)"),
  spacer(60),

  h2("5.3 Differential Diagnosis of Alcohol-Related Seizures"),
  para("Always exclude other etiologies before attributing seizures solely to withdrawal:"),
  spacer(60),
  makeTable(
    ["Category", "Examples"],
    [
      ["Drug withdrawal", "Benzodiazepine, barbiturate, baclofen, or other sedative withdrawal"],
      ["Structural / trauma", "Intracranial hemorrhage (subdural, epidural, ICH), contusion"],
      ["Infection", "Meningitis, encephalitis, cerebral abscess"],
      ["Metabolic", "Hypoglycemia, hyponatremia, hypernatremia, hypocalcemia, hepatic failure"],
      ["Toxic ingestion", "Cocaine, amphetamines, anticholinergics, isoniazid, organophosphates, TCA, lithium, salicylates"],
      ["Vascular", "Ischemic stroke, cerebral venous thrombosis"],
      ["Epilepsy", "Non-compliance with anticonvulsants; idiopathic or post-traumatic epilepsy exacerbated by alcohol"],
      ["Other", "Sleep deprivation, hypertensive encephalopathy, carbon monoxide poisoning"],
    ],
    [30, 70]
  ),
  spacer(60),
  para("The presence of focal seizures, focal postictal deficits, fever, or failure to return to baseline should prompt CT head and LP (if no contraindication). (Rosen's Emergency Medicine)"),
  spacer(),

  // ── SECTION 6: Emergency Management ──────────────────────────────────
  h1("6. Emergency Management"),

  h2("6.1 Immediate Stabilization"),
  bullet("Secure IV access"),
  bullet("Continuous cardiac monitoring and pulse oximetry"),
  bullet("Check capillary glucose immediately — correct hypoglycemia"),
  bullet("Assess airway — aspiration risk is high in agitated or seizing patients"),
  bullet("Give thiamine 100 mg IV/IM BEFORE any glucose-containing fluids (prevent Wernicke's)"),
  bullet("Supplemental oxygen; prepare for possible intubation in refractory cases"),
  spacer(60),

  warningBox("THIAMINE FIRST: Always administer thiamine 100 mg IV before giving dextrose. Glucose without thiamine can precipitate Wernicke's encephalopathy in thiamine-deficient patients."),
  spacer(80),

  h2("6.2 Benzodiazepines — First-Line Treatment"),
  para("Benzodiazepines are the treatment of choice for alcohol withdrawal seizures due to their GABA-A potentiation, which both terminates active seizures and raises the seizure threshold to prevent recurrence. All benzodiazepines are equally efficacious; however, lorazepam IV is the only agent shown in trials to reduce seizure recurrence and decrease the need for hospitalization (NNT = 5 to prevent additional seizures in the subsequent 6 hours). (Rosen's Emergency Medicine)"),
  spacer(80),
  makeTable(
    ["Drug", "Dose", "Route", "Onset", "Key Notes"],
    [
      ["Lorazepam (preferred)", "2-4 mg; repeat every 15-20 min, doubling dose", "IV (IM adequate)", "5-20 min", "Only BZD proven to reduce recurrence; preferred in liver disease (no active metabolites)"],
      ["Diazepam", "10-20 mg IV over 2 min; repeat every 5-10 min, doubling", "IV only (IM absorption erratic)", "1-5 min", "Long-acting active metabolites (20-30 hr) provide self-tapering; fastest onset"],
      ["Midazolam", "2-4 mg IM or IV; titrate", "IV or IM", "2-5 min", "Useful when IV access unavailable; short-acting"],
      ["Chlordiazepoxide", "50-100 mg PO every 4-6 h (tapering)", "PO", "~30 min", "For outpatient/non-acute withdrawal; not for active seizures"],
      ["Oxazepam", "15-30 mg PO TID-QID (tapering)", "PO", "~30 min", "Safe in liver disease; no active metabolites; not for active seizures"],
    ],
    [18, 22, 14, 12, 34]
  ),
  spacer(60),
  para("Symptom-triggered therapy (guided by CIWA-Ar) is recommended over fixed-schedule dosing — it uses less total drug and results in shorter treatment duration. (Tintinalli's Emergency Medicine)"),
  spacer(60),

  h2("6.3 Endpoint of Benzodiazepine Therapy"),
  para("The target endpoint is light somnolence — the patient is sedated but arousable when stimulated. Over-sedation should be avoided to preserve airway reflexes. After achieving this endpoint, transition to maintenance therapy with scheduled doses, periodic boluses, or continuous infusion."),
  spacer(60),

  h2("6.4 Refractory Withdrawal Seizures"),
  para("Consider benzodiazepine-refractory status when the patient fails to respond after 40-50 mg diazepam equivalents per hour or 10-20 mg lorazepam in the first hour. At this point, additional agents are required:"),
  spacer(80),
  makeTable(
    ["Agent", "Dose", "Notes"],
    [
      ["Phenobarbital", "65 mg IV every 15-30 min; max 260 mg", "Effective adjunct/alternative; systematic review evidence (PMID 37060631, 37589203) supports use in ED; higher respiratory depression risk — prepare for intubation"],
      ["Propofol", "5 mcg/kg/min (0.3 mg/kg/hr) IV infusion, titrate to effect", "Requires intubation and ICU; hypotension risk; propofol infusion syndrome if >48 h at >5 mg/kg/hr (dysrhythmias, rhabdomyolysis, metabolic acidosis)"],
      ["Ketamine infusion", "0.012 - 1.6 mg/kg/hr IV", "Emerging adjunct in refractory cases; dissociative anesthetic; does not depress respiratory drive at sub-anesthetic doses"],
      ["Dexmedetomidine", "Titrated IV infusion", "Reduces benzodiazepine requirement; less respiratory depression; adjunct only — does not address seizure threshold"],
    ],
    [20, 30, 50]
  ),
  spacer(60),
  warningBox("PHENYTOIN IS NOT EFFECTIVE for alcohol withdrawal seizures and may lower the seizure threshold. Do NOT use phenytoin for AWS prophylaxis or treatment. (Tintinalli's EM; Bradley & Daroff's Neurology)"),
  spacer(80),

  h2("6.5 Status Epilepticus in AWS"),
  para("Status epilepticus (SE) is rare in isolated alcohol withdrawal (<3%) but constitutes a medical emergency. When SE occurs in the context of alcohol withdrawal:"),
  bullet("Follow standard SE management: benzodiazepines → second-line agents"),
  bullet("Phenobarbital is preferred over phenytoin as second-line for AWS-related SE"),
  bullet("The presence of SE should prompt investigation for concurrent structural, metabolic, or infectious cause"),
  bullet("Intubation and ICU admission are typically required"),
  spacer(60),

  h2("6.6 Adjunctive & Supportive Care"),
  makeTable(
    ["Intervention", "Details"],
    [
      ["Thiamine", "100 mg IV/IM daily — BEFORE glucose; continue until normal diet resumes. Prevents/treats Wernicke's encephalopathy"],
      ["Folate", "1 mg daily IV/PO — commonly deficient in chronic alcohol use"],
      ["Fluids", "IV fluid resuscitation — patients are often severely dehydrated"],
      ["Electrolytes", "Correct hypokalemia, hypomagnesemia (give MgSO4 if hypomagnesemia confirmed), hypophosphatemia"],
      ["Glucose", "Monitor and correct; give thiamine first before dextrose"],
      ["Multivitamins", "IV multivitamin supplementation as tolerated"],
      ["Aspiration precautions", "Side-lying position; high aspiration risk in seizing or agitated patients"],
      ["Beta-blockers / Clonidine", "Adjuncts to control autonomic hyperactivity (tachycardia, hypertension); do NOT prevent seizures — use only alongside benzodiazepines"],
      ["Carbamazepine", "Alternative to BZDs in low-risk uncomplicated withdrawal (not for active seizures or DTs); shown efficacious in select patients (2026 evidence — PMID 42095715)"],
    ],
    [25, 75]
  ),
  spacer(),

  // ── SECTION 7: Algorithm ─────────────────────────────────────────────
  h1("7. Management Algorithm"),
  spacer(60),
  new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [
      new TableRow({ children: [new TableCell({
        shading: { type: ShadingType.SOLID, color: DARK_BLUE },
        borders: { top: noBorder, bottom: noBorder, left: noBorder, right: noBorder },
        margins: { top: 100, bottom: 100, left: 200, right: 200 },
        children: [new Paragraph({ alignment: AlignmentType.CENTER, children: [new TextRun({ text: "PATIENT WITH SUSPECTED ALCOHOL WITHDRAWAL SEIZURE", bold: true, color: WHITE, size: 22, font: "Calibri" })] })],
      })] }),
      new TableRow({ children: [new TableCell({
        shading: { type: ShadingType.SOLID, color: LIGHT_GREY },
        borders: { top: noBorder, bottom: noBorder, left: noBorder, right: noBorder },
        margins: { top: 80, bottom: 80, left: 200, right: 200 },
        children: [
          new Paragraph({ alignment: AlignmentType.CENTER, children: [new TextRun({ text: "IMMEDIATE STEPS (SIMULTANEOUS)", bold: true, color: DARK_BLUE, size: 20, font: "Calibri" })] }),
          new Paragraph({ alignment: AlignmentType.CENTER, children: [new TextRun({ text: "IV access · Cardiac monitor · O2/SpO2 · Glucose check · THIAMINE 100 mg IV · Airway assessment", size: 18, font: "Calibri", color: DARK_TEXT })] }),
        ],
      })] }),
      new TableRow({ children: [new TableCell({
        shading: { type: ShadingType.SOLID, color: LIGHT_BLUE },
        borders: { top: noBorder, bottom: noBorder, left: noBorder, right: noBorder },
        margins: { top: 80, bottom: 80, left: 200, right: 200 },
        children: [
          new Paragraph({ alignment: AlignmentType.CENTER, children: [new TextRun({ text: "ASSESS SEVERITY — CIWA-Ar Score", bold: true, color: DARK_BLUE, size: 20, font: "Calibri" })] }),
        ],
      })] }),
      new TableRow({ children: [new TableCell({
        shading: { type: ShadingType.SOLID, color: WHITE },
        borders: { top: thinBorder, bottom: thinBorder, left: noBorder, right: noBorder },
        margins: { top: 80, bottom: 80, left: 200, right: 200 },
        children: [
          new Paragraph({ children: [new TextRun({ text: "FIRST-LINE: Benzodiazepine", bold: true, color: MED_BLUE, size: 20, font: "Calibri" })] }),
          new Paragraph({ children: [new TextRun({ text: "Lorazepam 2-4 mg IV (preferred) — OR — Diazepam 10-20 mg IV", size: 18, font: "Calibri", color: DARK_TEXT })] }),
          new Paragraph({ children: [new TextRun({ text: "Double dose and repeat every 5-20 minutes until light somnolence (arousable on stimulation)", size: 18, font: "Calibri", color: DARK_TEXT })] }),
        ],
      })] }),
      new TableRow({ children: [new TableCell({
        shading: { type: ShadingType.SOLID, color: LIGHT_GREY },
        borders: { top: noBorder, bottom: noBorder, left: noBorder, right: noBorder },
        margins: { top: 80, bottom: 80, left: 200, right: 200 },
        children: [
          new Paragraph({ children: [new TextRun({ text: "No response after 40-50 mg diazepam equiv. / 10-20 mg lorazepam?", bold: true, color: ACCENT, size: 20, font: "Calibri" })] }),
          new Paragraph({ children: [new TextRun({ text: "→ REFRACTORY: Add Phenobarbital 65 mg IV q15-30 min (max 260 mg)", size: 18, font: "Calibri", color: DARK_TEXT })] }),
          new Paragraph({ children: [new TextRun({ text: "→ OR Propofol infusion + INTUBATION + ICU", size: 18, font: "Calibri", color: DARK_TEXT })] }),
          new Paragraph({ children: [new TextRun({ text: "→ OR Ketamine infusion adjunct (0.012-1.6 mg/kg/hr)", size: 18, font: "Calibri", color: DARK_TEXT })] }),
        ],
      })] }),
      new TableRow({ children: [new TableCell({
        shading: { type: ShadingType.SOLID, color: DARK_BLUE },
        borders: { top: noBorder, bottom: noBorder, left: noBorder, right: noBorder },
        margins: { top: 80, bottom: 80, left: 200, right: 200 },
        children: [
          new Paragraph({ children: [new TextRun({ text: "SUPPORTIVE: Fluids · Electrolytes · Folate · Monitor for DTs", bold: true, color: WHITE, size: 18, font: "Calibri" })] }),
          new Paragraph({ children: [new TextRun({ text: "MONITOR: CIWA-Ar hourly · Vitals · Glucose · Electrolytes · Aspiration precautions", color: LIGHT_BLUE, size: 18, font: "Calibri" })] }),
        ],
      })] }),
    ],
  }),
  spacer(),

  // ── SECTION 8: Disposition ────────────────────────────────────────────
  h1("8. Disposition"),
  makeTable(
    ["Clinical Scenario", "Disposition"],
    [
      ["Single uncomplicated AWS + rapid return to baseline + no DT features + reliable social support", "Consider discharge with short BZD taper + close outpatient follow-up"],
      ["Multiple seizures, CIWA-Ar >15, or incomplete workup", "Admission — medical ward with close monitoring"],
      ["History of DTs, prior complicated withdrawal, or medical comorbidity", "Inpatient admission — consider step-down or monitored bed"],
      ["Refractory seizures, benzodiazepine-resistant withdrawal, DTs, or requirement for intubation", "ICU admission"],
      ["First-ever seizure or atypical features (focal, fever, altered consciousness)", "Admission + full workup (CT head, LP if indicated, metabolic panel)"],
    ],
    [40, 60]
  ),
  spacer(80),
  para("In-patient detoxification is mandatory when there is: (1) history of withdrawal seizures or DTs; (2) heavy consumption >30 units/day; (3) concurrent psychiatric or physical illness; (4) benzodiazepine or other sedative co-use; (5) pregnancy; or (6) prior failed community detoxification. (Maudsley Prescribing Guidelines, 15th ed.)"),
  spacer(),

  // ── SECTION 9: Special Populations ───────────────────────────────────
  h1("9. Special Populations"),
  h2("9.1 Liver Disease"),
  para("In patients with significant hepatic impairment, avoid long-acting benzodiazepines with active metabolites (diazepam, chlordiazepoxide). Prefer lorazepam or oxazepam — both undergo direct glucuronidation without hepatic cytochrome metabolism and have no active metabolites."),
  spacer(60),

  h2("9.2 Concurrent Benzodiazepine Dependence"),
  para("Benzodiazepine withdrawal can produce a clinically identical syndrome to alcohol withdrawal DTs. Combined withdrawal may be more severe and prolonged, and require higher doses. Document current benzodiazepine use carefully."),
  spacer(60),

  h2("9.3 Pregnancy"),
  para("Alcohol withdrawal in pregnancy is an obstetric emergency. Fetal risk from untreated withdrawal exceeds medication risk. Benzodiazepines remain the treatment of choice despite teratogenic concerns. Inpatient management with obstetric co-management is mandatory."),
  spacer(60),

  h2("9.4 Elderly Patients"),
  para("Elderly patients have reduced CNS reserve and are at higher risk for severe withdrawal. They are also at greater risk of benzodiazepine-related respiratory depression and falls. Use lower initial doses with careful titration. Prefer lorazepam or oxazepam (predictable pharmacokinetics)."),
  spacer(),

  // ── SECTION 10: Recent Evidence ──────────────────────────────────────
  h1("10. Recent Evidence (2023-2026)"),
  makeTable(
    ["Study / PMID", "Key Finding"],
    [
      ["Skryabin et al., J Psychiatr Pract 2026 (PMID 42095715)", "Comprehensive review: BZDs remain first-line; carbamazepine viable adjunct/alternative in selected cases. Genetic polymorphisms (SLC6A3, APOE) and hippocampal neurogenesis dysregulation are emerging pathophysiological targets."],
      ["Pourmand et al., Am J Emerg Med 2023 (PMID 37060631)", "Systematic review & meta-analysis: Phenobarbital-based approach effective for AWS; associated with lower ICU admission rates vs. BZD-only protocols."],
      ["Punia et al. (SAEM GRACE), Acad Emerg Med 2024 (PMID 37589203)", "Systematic review: Direct evidence supports phenobarbital use in the ED for AWS management with favorable outcomes."],
      ["Shirk & Reinert, J Clin Pharmacol 2025 (PMID 39415533)", "Systematic review: Propofol is a viable rescue/salvage agent in refractory AWS requiring ICU-level care; caution re. propofol infusion syndrome with prolonged use."],
    ],
    [35, 65]
  ),
  spacer(),

  // ── SECTION 11: Key Points ────────────────────────────────────────────
  h1("11. Key Clinical Takeaways"),
  spacer(60),
  infoBox("Summary: 10 Points to Remember", [
    "1.  Peak seizure risk is 24-48 hours after the last drink; can occur up to 2 weeks later.",
    "2.  90% of AWS are generalized tonic-clonic; multiple seizures in 60% within a 6-hour period.",
    "3.  1 in 3 patients who seize will develop delirium tremens — monitor closely for 48-96 hours.",
    "4.  THIAMINE 100 mg IV before any glucose — prevent Wernicke's encephalopathy.",
    "5.  Benzodiazepines are first-line: escalating doses until light somnolence (arousable when stimulated).",
    "6.  Lorazepam IV is the only BZD proven to reduce seizure recurrence (NNT = 5).",
    "7.  PHENYTOIN IS INEFFECTIVE — do not use for alcohol withdrawal seizures.",
    "8.  Refractory AWS: add phenobarbital; escalate to propofol/intubation if still uncontrolled.",
    "9.  Correct electrolytes: hypokalemia, hypomagnesemia, hypophosphatemia are common.",
    "10. Kindling: each withdrawal episode lowers the seizure threshold — treat early and aggressively.",
  ]),
  spacer(),

  // ── SECTION 12: References ────────────────────────────────────────────
  h1("12. References"),
  bullet("Tintinalli JE et al. Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 9th ed. McGraw-Hill. 2020."),
  bullet("Rosen's Emergency Medicine: Concepts and Clinical Practice, 9th ed. Elsevier. 2023."),
  bullet("Bradley WG, Daroff RB et al. Bradley and Daroff's Neurology in Clinical Practice, 8th ed. Elsevier. 2021."),
  bullet("Kaplan HI, Sadock BJ. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 11th ed. Wolters Kluwer. 2024."),
  bullet("Rakel RE. Textbook of Family Medicine, 9th ed. Elsevier. 2016."),
  bullet("Harrison's Principles of Internal Medicine, 22nd ed. McGraw Hill. 2025."),
  bullet("Skryabin V, Malygina A, Sokolova S. Alcohol Withdrawal Seizures: Neurobiological Mechanisms, Clinical Predictors, and Evidence-Based Management. J Psychiatr Pract. 2026 May;PMID 42095715."),
  bullet("Pourmand A et al. Evaluation of phenobarbital based approach in treating patient with alcohol withdrawal syndrome: A systematic review and meta-analysis. Am J Emerg Med. 2023 Jul;PMID 37060631."),
  bullet("Punia K, Scott W, Manuja K. SAEM GRACE: Phenobarbital for alcohol withdrawal management in the emergency department. Acad Emerg Med. 2024 May;PMID 37589203."),
  bullet("Shirk L, Reinert JP. The Role of Propofol in Alcohol Withdrawal Syndrome: A Systematic Review. J Clin Pharmacol. 2025 Feb;PMID 39415533."),
];

// ── Build Document ───────────────────────────────────────────────────────────
const doc = new Document({
  styles: {
    paragraphStyles: [
      {
        id: "Heading1", name: "Heading 1", basedOn: "Normal",
        next: "Normal", quickFormat: true,
        run: { size: 28, bold: true, color: DARK_BLUE, font: "Calibri" },
        paragraph: { spacing: { before: 360, after: 120 } },
      },
      {
        id: "Heading2", name: "Heading 2", basedOn: "Normal",
        next: "Normal", quickFormat: true,
        run: { size: 24, bold: true, color: MED_BLUE, font: "Calibri" },
        paragraph: { spacing: { before: 280, after: 80 } },
      },
      {
        id: "Heading3", name: "Heading 3", basedOn: "Normal",
        next: "Normal", quickFormat: true,
        run: { size: 22, bold: true, color: DARK_BLUE, font: "Calibri" },
        paragraph: { spacing: { before: 200, after: 60 } },
      },
    ],
  },
  sections: [
    {
      headers: {
        default: new Header({
          children: [
            new Table({
              width: { size: 100, type: WidthType.PERCENTAGE },
              rows: [new TableRow({
                children: [
                  new TableCell({
                    borders: { top: noBorder, bottom: { style: BorderStyle.SINGLE, size: 6, color: MED_BLUE }, left: noBorder, right: noBorder },
                    children: [new Paragraph({
                      children: [new TextRun({ text: "Alcohol Withdrawal Seizures — Clinical Reference", bold: true, color: DARK_BLUE, size: 18, font: "Calibri" })],
                    })],
                  }),
                  new TableCell({
                    borders: { top: noBorder, bottom: { style: BorderStyle.SINGLE, size: 6, color: MED_BLUE }, left: noBorder, right: noBorder },
                    children: [new Paragraph({
                      alignment: AlignmentType.RIGHT,
                      children: [
                        new TextRun({ text: "Page ", size: 18, color: "888888", font: "Calibri" }),
                        new TextRun({ children: [PageNumber.CURRENT], size: 18, color: "888888", font: "Calibri" }),
                        new TextRun({ text: " of ", size: 18, color: "888888", font: "Calibri" }),
                        new TextRun({ children: [PageNumber.TOTAL_PAGES], size: 18, color: "888888", font: "Calibri" }),
                      ],
                    })],
                  }),
                ],
              })],
            }),
          ],
        }),
      },
      footers: {
        default: new Footer({
          children: [new Paragraph({
            alignment: AlignmentType.CENTER,
            children: [new TextRun({
              text: "For clinical reference only. Always apply individual clinical judgment. Sources: Tintinalli · Rosen · Bradley & Daroff · Kaplan & Sadock · Harrison's · PubMed",
              size: 14, color: "999999", font: "Calibri", italics: true,
            })],
          })],
        }),
      },
      children: [
        ...titlePage(),
        ...sections,
      ],
    },
  ],
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync('/home/daytona/workspace/alcohol-withdrawal-seizures/Alcohol_Withdrawal_Seizures.docx', buffer);
  console.log('SUCCESS: Document written.');
}).catch(err => {
  console.error('ERROR:', err);
  process.exit(1);
});